argenx SE (LON:0QW0)
United Kingdom · Delayed Price · Currency is GBP · Price in EUR | Market Cap | 41.66B +7.3% |
| Revenue (ttm) | 4.46B +60.6% |
| Net Income | 1.41B +22.4% |
| EPS | 21.30 +24.1% |
| Shares Out | n/a |
| PE Ratio | 31.26 |
| Forward PE | 24.30 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 130,069 |
| Open | 790.00 |
| Previous Close | 777.00 |
| Day's Range | 755.00 - 800.80 |
| 52-Week Range | 569.00 - 924.70 |
| Beta | -0.04 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 22, 2026 |
About argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, system... [Read more]
Financial Performance
In 2025, argenx SE's revenue was $4.24 billion, an increase of 88.44% compared to the previous year's $2.25 billion. Earnings were $1.29 billion, an increase of 55.10%.
Financial numbers in USD Financial StatementsNews
argenx SE Reports Third Quarter 2026 Financial Results and Business Update
argenx SE reported its third quarter 2026 financial results, highlighted by global product net sales of $1.7 billion for VYVGART, representing 54% year-over-year growth and 13% quarter-over-quarter gr...
What argenex (ARGX) Said on Its Q3 Earnings Call
argenex NASDAQ: ARGX reported third-quarter 2026 product net sales of $1.7 billion, up 54% from a year earlier and 13% sequentially, as patient growth in generalized myasthenia gravis, or MG, and chro...
Argenx Slumps On Mixed Third Quarter, Surprise Vyvgart Testing Plans
Argenx stock fell early Thursday despite beating sales expectations on a surprise testing requirement for its drug, Vyvgart.
Argenx Q3 Net Income Rises As VYVGART Sales Increase
(RTTNews) - Argenx SE (ARGX) reported on Thursday higher third-quarter net income and product sales, reflecting continued growth of its VYVGART franchise.
argenx SE Earnings Call Transcript: Q3 2026
Q3 product sales rose 54% YoY to $1.7B, while adjusted operating margin was 37% excluding Forte transaction costs. Pipeline and launch plans broaden the 2027 growth opportunity, though key clinical and regulatory outcomes remain pending.
argenx SE Earnings release: Q3 2026
argenx SE released its Q3 2026 earnings on October 22, 2026, summarizing the period's financial results.
argenx SE Slides: Q3 2026
argenx SE has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 22, 2026.
argenx SE Reports Strong Q3 Earnings, Shares Trade Well Below GF Value™ (ARGX)
argenx SE Reports Strong Q3 Earnings, Shares Trade Well Below GF Value™ (ARGX)
Argenx Earnings Up In Q3
(RTTNews) - argenx SE (ARGX), an immunology innovation company, on Thursday reported higher net income in the third quarter compared with the previous year.
IBB, REGN, NTRA, ARGX: Large Outflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Biotechnology ETF (Symbol: IBB) where we have detected an appr...
Citi Initiates Upside Catalyst Watch on Argenx (ARGX) Ahead of Phase 3 Data
Citi Initiates Upside Catalyst Watch on Argenx (ARGX) Ahead of Phase 3 Data
Citi adds ‘upside 90-day catalyst watch’ on Argenx
Citi added an “upside 90-day catalyst watch” on Argenx (ARGX) while keeping a Buy rating on the shares with a $1,301 price target The company later this quarter will report…
ARGX Maintained by RBC Capital -- Price Target Lowered to $1025
ARGX Maintained by RBC Capital -- Price Target Lowered to $1025
Argenx price target lowered to $1,025 from $1,100 at RBC Capital
RBC Capital lowered the firm’s price target on Argenx (ARGX) to $1,025 from $1,100 but keeps an Outperform rating on the shares. The stock has been volatile lately, “round tripping”…
Argenx reports ALKIVIA study meets primary endpoint
Argenx (ARGX) announced that new data from the Phase 3 study evaluating Vyvgart Hytrulo in patients with autoimmune myositis, focused on immune-mediated necrotizing myopathy, or IMNM, and dermatomyosi...
Zacks Investment Ideas feature highlights: Cummins, Argenx and PACCAR
Cummins, Argenx and PACCAR offer potential buying opportunities after recent pullbacks, backed by strong earnings growth, improving forecasts and long-term business drivers.
argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026
October 15, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will host a conference call and audio webcast on Thursda...
ARGX Maintained by Wells Fargo -- Price Target Raised to $1356
ARGX Maintained by Wells Fargo -- Price Target Raised to $1356
Argenx price target raised to $1,356 from $1,355 at Wells Fargo
Wells Fargo raised the firm’s price target on Argenx (ARGX) to $1,356 from $1,355 and keeps an Overweight rating on the shares ahead of quarterly results. The firm notes Q3…
ARGX Investors with $100,000 in Losses Have Opportunity to Join argenx SE Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $ARGX--ARGX Investors with $100,000 in Losses Have Opportunity to Join argenx SE Fraud Investigation with SBS Law.
ARGX Maintains by Oppenheimer -- Price Target Lowered to $1038
ARGX Maintains by Oppenheimer -- Price Target Lowered to $1038
Argenx price target lowered to $1,038 from $1,100 at Oppenheimer
Oppenheimer analyst Leland Gershell lowered the firm’s price target on Argenx (ARGX) to $1,038 from $1,100 and keeps an Outperform rating on the shares. The firm is updating its model…
Argenx price target raised to $1,157 from $1,136 at BofA
BofA raised the firm’s price target on Argenx (ARGX) to $1,157 from $1,136 and keeps a Buy rating on the shares. The firm models Q3 Vyvgart revenues of $1.63B, reflecting…
ARGX Maintains Rating by Evercore ISI Group -- Price Target Lowers to $1078
ARGX Maintains Rating by Evercore ISI Group -- Price Target Lowers to $1078
ARGX Maintained by Baird -- Price Target Lowered to $823
ARGX Maintained by Baird -- Price Target Lowered to $823